A Novel Method to Estimate Donor-Derived Cell-Free DNA in Pregnant Kidney Transplant Recipients: A Proof-of-Concept Study

IF 0.8 4区医学 Q4 IMMUNOLOGY

Transplantation proceedings Pub Date : 2025-04-28 DOI:10.1016/j.transproceed.2025.03.025

Jessica Tang , Lior Kashani Ligumsky , Kate Woodruff , Christine Jang , Nicole Charland , Nour Al Haj Baddar , Ebad Ahmed , Paul Van Hummelen , Gabrielle Heilek , Bernhard Zimmermann , Suphamai Bunnapradist , Hossein Tabriziani , Yalda Afshar

{"title":"A Novel Method to Estimate Donor-Derived Cell-Free DNA in Pregnant Kidney Transplant Recipients: A Proof-of-Concept Study","authors":"Jessica Tang , Lior Kashani Ligumsky , Kate Woodruff , Christine Jang , Nicole Charland , Nour Al Haj Baddar , Ebad Ahmed , Paul Van Hummelen , Gabrielle Heilek , Bernhard Zimmermann , Suphamai Bunnapradist , Hossein Tabriziani , Yalda Afshar","doi":"10.1016/j.transproceed.2025.03.025","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Pregnant kidney transplant recipients (KTRs) are a vulnerable, high-risk population, susceptible to obstetrical complications, as well as graft rejection. Current methods used to monitor kidney transplant function lack specificity. Recently, donor derived cell-free DNA (dd-cfDNA) has emerged as a non-invasive biomarker for assessing risk for allograft rejection in KTRs. However, utilizing dd-cfDNA to monitor allograft status in pregnant KTRs requires the ability to distinguish between fetal/placental, donor, and KTR derived cfDNA.</div></div><div><h3>Methods</h3><div>We developed a custom bioinformatics analysis to identify and measure dd-cfDNA in 6 pregnant KTRs by sequencing maternal cfDNA (blood sample) and paternal genomic DNA (buccal swab).</div></div><div><h3>Results</h3><div>We demonstrate our ability to successfully measure dd-cfDNA in 4/6 pregnant KTRs.</div></div><div><h3>Conclusions</h3><div>This proof-of-concept study demonstrates that dd-cfDNA can be measured in pregnant KTRs. This study lays the foundation for future research on dd-cfDNA correlations with maternal fetal conditions to help improve allograft care for this specific patient population.</div></div>","PeriodicalId":23246,"journal":{"name":"Transplantation proceedings","volume":"57 5","pages":"Pages 706-712"},"PeriodicalIF":0.8000,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplantation proceedings","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S004113452500226X","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Pregnant kidney transplant recipients (KTRs) are a vulnerable, high-risk population, susceptible to obstetrical complications, as well as graft rejection. Current methods used to monitor kidney transplant function lack specificity. Recently, donor derived cell-free DNA (dd-cfDNA) has emerged as a non-invasive biomarker for assessing risk for allograft rejection in KTRs. However, utilizing dd-cfDNA to monitor allograft status in pregnant KTRs requires the ability to distinguish between fetal/placental, donor, and KTR derived cfDNA.

Methods

We developed a custom bioinformatics analysis to identify and measure dd-cfDNA in 6 pregnant KTRs by sequencing maternal cfDNA (blood sample) and paternal genomic DNA (buccal swab).

Results

We demonstrate our ability to successfully measure dd-cfDNA in 4/6 pregnant KTRs.

Conclusions

This proof-of-concept study demonstrates that dd-cfDNA can be measured in pregnant KTRs. This study lays the foundation for future research on dd-cfDNA correlations with maternal fetal conditions to help improve allograft care for this specific patient population.

查看原文本刊更多论文

一种评估妊娠肾移植受者供体来源无细胞DNA的新方法：一项概念验证研究。

背景：妊娠肾移植受者（KTRs）是一个脆弱的高危人群，容易发生产科并发症，以及移植排斥反应。目前用于监测肾移植功能的方法缺乏特异性。最近，供体来源的无细胞DNA （dd-cfDNA）已成为评估KTRs异体移植排斥风险的非侵入性生物标志物。然而，利用dd-cfDNA监测妊娠KTR的异体移植物状态需要能够区分胎儿/胎盘、供体和KTR衍生的cfDNA。方法：采用定制的生物信息学分析方法，对6例妊娠ktr患者的母体cfDNA（血样）和父系基因组DNA（口腔拭子）进行测序，鉴定和测定dd-cfDNA。结果：我们证明了我们能够成功测量4/6妊娠ktr的dd-cfDNA。结论：这项概念验证研究表明，dd-cfDNA可以在怀孕的ktr中检测到。本研究为进一步研究dd-cfDNA与母胎状况的相关性奠定了基础，有助于改善对这一特定患者群体的同种异体移植护理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Transplantation proceedings 医学-免疫学

CiteScore

1.70

自引率

0.00%

发文量

502

审稿时长

60 days

期刊介绍： Transplantation Proceedings publishes several different categories of manuscripts, all of which undergo extensive peer review by recognized authorities in the field prior to their acceptance for publication. The first type of manuscripts consists of sets of papers providing an in-depth expression of the current state of the art in various rapidly developing components of world transplantation biology and medicine. These manuscripts emanate from congresses of the affiliated transplantation societies, from Symposia sponsored by the Societies, as well as special Conferences and Workshops covering related topics. Transplantation Proceedings also publishes several special sections including publication of Clinical Transplantation Proceedings, being rapid original contributions of preclinical and clinical experiences. These manuscripts undergo review by members of the Editorial Board. Original basic or clinical science articles, clinical trials and case studies can be submitted to the journal?s open access companion title Transplantation Reports.